Roswell Park Oncologists and Scientists Bring Latest Research Findings to ASCO 2023

BUFFALO, N.Y. — Oncologists, epidemiologists and basic, translational and clinical researchers from Roswell Park Comprehensive Cancer Center have been invited to present their own research surrounding cancer management, ongoing clinical trials and more at the annual meeting of the American Society of Clinical Research (ASCO), happening online and in-person from McCormick Place in Chicago, Illinois, June 2 to 6.

The Roswell Park-led studies to be featured during ASCO 2023 include podium presentations highlighting clinical studies in patients with colorectal cancer and breast cancer, as well as a poster abstract highlighting new research on the impact of physical activity in patients with multiple myeloma.

• Deepak Vadehra, DO, is first author and presenter and Sarbajit Mukherjee, MD, MS, is senior author on “Transcriptional metabolic profiling in young onset colorectal cancer (CRC) patients.” This podium presentation happening during the Clinical Science Symposium “Molecular Basis for Young-Onset Colorectal Cancer” highlights a Roswell Park clinical study that looked at differences in transcriptional metabolic profiles and in immune profiles between younger and older patients with colorectal cancer.
  • Abstract: 3509
  • Saturday, June 3, 4:30 p.m. CDT in Hall D2
     
• Jasmin Gill, a student at the University at Buffalo, is first author and Anurag Singh, MD, is senior author on “Racial/ethnic differences in 21-gene recurrence score and survival among estrogen receptor-positive breast cancer patients.” This oral presentation focuses on work led at Roswell Park by Dr. Singh evaluating disparities within an observational cohort study.
  • Abstract: 511
  • Saturday, June 3, session begins 4:30 p.m. CDT in E451
     
• Janine Joseph, MS, is first author and Jens Hillengass, MD, PhD, is senior author on “T cell exhaustion is lower after a physical activity intervention in multiple myeloma patients,” a poster abstract in the Hematologic Malignancies session. The research team looked at two dozen multiple myeloma patients who completed six months of either supervised resistance trainings or wore an activity tracker and examined changes in their immune systems.
  • Abstract #8060, poster board #52
  • Monday, June 5, 8 a.m.–noon CDT

Special roles and recognitions

• Igor Puzanov, MD, MSCI, is chairing an education session, The Evolving Management of Stage IV Melanoma, to be held Tuesday, June 6, from 11:30 a.m. to 12:45 p.m. CDT in S100bc.
• Benjamin Switzer, MD, is first author and Dr. Puzanov is senior author on “Evolving Management of Stage IV Melanoma,” a chapter in the ASCO Educational Book for the 2023 Annual Meeting.
• Changchuan Jiang, MD, MPH, a Roswell Park clinical fellow, received a 2023 ASCO Annual Meeting Merit Award from Conquer Cancer, the ASCO Foundation. Merit Awards recognize students, trainees and junior faculty for contributions to their fields and research advancements within the cancer care community.
• Kara Kelly, MD, Chair of Pediatric Oncology, is a lead contributor representing Children's Oncology Group on SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL), to be highlighted in a Sunday, June 4, plenary session as well as a press program. 

Additional poster presentations

Five Roswell Park teams will present Trials in Progress Submission (TPS) abstracts highlighting studies currently underway and/or open to accrual:

• Prantesh Jain, MD, FACP, is first author on “Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients,” a poster abstract in the Developmental Therapeutics—Immunotherapy session
  • Abstract: TPS2677, poster board #512a
  • Saturday, June 3, 8–11 a.m. CDT in Hall A
     
• Sai Yendamuri, MD, is senior author on "Metformin for chemoprevention of lung cancer in high-risk overweight or obese individuals," a poster abstract in the Prevention, Risk Reduction, and Hereditary Cancer poster session
  • Abstract TPS10636, poster board #269a
  • Saturday, June 3, 1:15 – 4:15 p.m. CDT in Hall A
     
• Shipra Gandhi, MD, is first author and Pawel Kalinski, PhD, is senior author on “Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer,” a poster abstract in the Breast Cancer–Metastatic session
  • Abstract TPS1112, poster board #332b
  • Sunday, June 4, 8–11 a.m. CDT in Hall A
     
• Sarbajit Mukherjee, MD, is first author and Elizabeth Repasky, PhD, is senior author on “A phase 2 trial of chemotherapy, pembrolizumab, and propranolol in patients with advanced esophageal/gastroesophageal junction adenocarcinoma (EGAC),” a poster abstract in the Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary session
  • Abstract TPS4171, poster board #492a
  • Monday, June 5, 8–11 a.m. CDT in Hall A
     
• Eunice Wang, MD, is senior author on "Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia," a poster abstract to be presented in the Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant session
  • Abstract TPS7079, poster board #206a
  • Monday, June 5,  8–11 a.m. CDT in Hall A

These Roswell Park-led poster abstracts will report findings from a broad range of studies in population health, clinical oncology and care quality:

• Evan Davis, MPH, is first author and Rikki Cannioto, PhD, is senior author on “Does adherence to cancer prevention guidelines before diagnosis associate with improved cancer survival?” a poster abstract in the Prevention, Risk Reduction, and Hereditary Cancer session
  • Abstract 10582, poster board #215
  • Saturday, June 3, 1:15 PM – 4:15 PM CDT in Hall A
     
• Lei Deng, MD, is first author and Igor Puzanov, MD, MSCI, is senior author on “Risk of further progression or death among durable progression-free survivors with melanoma in PD-1 blockade trials: Implications for imaging surveillance,” a poster abstract in the Melanoma/Skin Cancers session
  • Abstract 9529, poster board #292
  • Saturday, June 3, 1:15 PM – 4:15 PM CDT in Hall A
     
• Changchuan Jiang, MD, MPH, is first author on “Beyond transportation: Financial hardship, food insecurity, and care access barriers among US cancer survivors with transportation barriers to care,” a poster abstract in the Health Services Research and Quality Improvement session
  • Abstract 6534, poster board #26
  • Saturday, June 3, 1:15 PM – 4:15 PM CDT in Hall A
     
• Rachel Frascati, PhD, is first author and Grace Dy, MD, is senior author on “Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC),” a poster abstract in the Lung Cancer—Non-Small Cell Metastatic session
  • Abstract 9135, poster board #123
  • Sunday, June 4, 8–11 a.m. CDT in Hall A
     
• Former Roswell Park intern Karen Huang, DrPH, MPH, is first author and Anurag Singh, MD, is senior author on “Long-term outcomes of single and five fraction schedules of stereotactic body radiation therapy for early-stage central or peripheral NSCLC: Neither fractionation nor location matter?” a poster abstract in the Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers session
  • Abstract 8538, poster board #165
  • Sunday, June 4, 8–11 a.m. CDT in Hall A
     
• Sung Jun Ma, MD, is first author and Anurag Singh, MD, is senior author on “Association of human epidermal growth factor receptor 2 expression with 21-gene recurrence score and survival among patients with estrogen receptor–positive breast cancer,” a poster abstract in the Breast Cancer—Local/Regional/Adjuvant session
  • Abstract 563, poster board #393
  • Sunday, June 4, 8–11 a.m. CDT in Hall A
     
• Pragati Gole Advani, DrPH, MPH, is first author on “Racial and ethnic disparities in risk of second primary malignancies among diffuse large B-cell lymphoma survivors,” a poster abstract in the Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia session
  • Abstract 7567, poster board #118
  • Monday, June 5, 8–11 a.m. CDT in Hall A
     
• Kohei Chida, MD, is first author and Kazuaki Takabe MD, PhD, FACS, is senior author on “Association of a high E2F targets score with survival in hepatocellular carcinoma patients,” a poster abstract in the Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary session
  • Abstract 4106, poster board #427
  • Monday, June 5, 8–11 a.m. CDT in Hall A
     
• Christos Fountzilas, MD, is senior author on “Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO),” a poster abstract in the Gastrointestinal Cancer—Colorectal and Anal session
  • Abstract 3590, poster board #290
  • Monday, June 5, 8–11 a.m. CDT in Hall A
     
• Khalid Shalaby, MBBCH, is first author on “Phase 2 study of abatacept, ixazomib, and dexamethasone in patients with relapsed/refractory multiple myeloma,” a poster abstract in the Hematologic Malignancies—Plasma Cell Dyscrasia session
  • Abstract 8030, poster board #22
  • Monday, June 5,  8–11 a.m. CDT in Hall A

###
 

NOTE TO MEDIA: Annie Deck-Miller, Director of Public Relations, will be working in the onsite ASCO 23 press room. To coordinate coverage or arrange an interview with Roswell Park experts, please contact her at annie.deck-miller@roswellpark.org or 716-602-5817

From the world’s first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide. Driven to eliminate cancer’s grip on humanity, the Roswell Park team of 4,000 makes compassionate, patient-centered cancer care and services accessible across New York State and beyond. Founded in 1898, Roswell Park was among the first three cancer centers nationwide to become a National Cancer Institute-designated comprehensive cancer center and is the only one to hold this designation in Upstate New York. To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit www.roswellpark.org, call 1-800-ROSWELL (1-800-767-9355) or email ASKRoswell@RoswellPark.org.